ID: ALA4744705

Max Phase: Preclinical

Molecular Formula: C16H20F2N8O2

Molecular Weight: 394.39

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(C(F)F)n1

Standard InChI:  InChI=1S/C16H20F2N8O2/c17-12(18)11-10(9-20-14(19)21-11)13-22-15(25-1-5-27-6-2-25)24-16(23-13)26-3-7-28-8-4-26/h9,12H,1-8H2,(H2,19,20,21)

Standard InChI Key:  VZVYLEDIUUZTCW-UHFFFAOYSA-N

Associated Targets(Human)

mTORC2 162 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

mTORC1 330 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-alpha subunit 12269 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase mTOR 13850 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 1A2 26471 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 2C19 29246 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 2D6 33882 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 3A4 53859 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

OVCAR-3 48710 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 394.39Molecular Weight (Monoisotopic): 394.1677AlogP: 0.52#Rotatable Bonds: 4
Polar Surface Area: 115.41Molecular Species: NEUTRALHBA: 10HBD: 1
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.33CX LogP: 1.58CX LogD: 1.58
Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.79Np Likeness Score: -1.21

References

1. Borsari C,Rageot D,Beaufils F,Bohnacker T,Keles E,Buslov I,Melone A,Sele AM,Hebeisen P,Fabbro D,Hillmann P,Wymann MP.  (2019)  Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.,  10  (10.0): [PMID:31620236] [10.1021/acsmedchemlett.9b00333]
2. Borsari C,Keles E,Rageot D,Treyer A,Bohnacker T,Bissegger L,De Pascale M,Melone A,Sriramaratnam R,Beaufils F,Hamburger M,Hebeisen P,Löscher W,Fabbro D,Hillmann P,Wymann MP.  (2020)  4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.,  63  (22.0): [PMID:33166139] [10.1021/acs.jmedchem.0c00620]
3. Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K..  (2022)  Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).,  238  [PMID:35688004] [10.1016/j.ejmech.2022.114498]

Source